Pluri (PLUR) Competitors

$2.37 0.00 (0.00%)

Closing price 05/22/2026 03:57 PM Eastern

Extended Trading

$2.31 -0.06 (-2.45%)

As of 05/22/2026 07:42 PM Eastern

PLUR vs. NRXP, COYA, AIFC, AADI, and ENGN

Should you buy Pluri stock or one of its competitors? MarketBeat compares Pluri with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pluri include NRx Pharmaceuticals (NRXP), Coya Therapeutics (COYA), ALT5 Sigma (AIFC), Aadi Bioscience (AADI), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does Pluri compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 25.9% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NRx Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Pluri has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Pluri	-2,162.08%	N/A	-106.59%

Pluri has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	94.85	-$28.62M	-$1.09	N/A
Pluri	$1.34M	19.08	-$22.58M	-$4.53	N/A

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 1,087.89%. Pluri has a consensus price target of $12.00, suggesting a potential upside of 406.33%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pluri had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 2 mentions for Pluri and 1 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.67 beat Pluri's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NRx Pharmaceuticals beats Pluri on 8 of the 15 factors compared between the two stocks.

How does Pluri compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Coya Therapeutics has a net margin of -266.10% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Pluri	-2,162.08%	N/A	-106.59%

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Comparatively, 25.9% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coya Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Pluri has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Pluri. Coya Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.19	-$21.23M	-$1.15	N/A
Pluri	$1.34M	19.08	-$22.58M	-$4.53	N/A

In the previous week, Pluri had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Pluri and 0 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.

Company	Overall Sentiment
Coya Therapeutics	Neutral
Pluri	Neutral

Coya Therapeutics currently has a consensus target price of $16.00, suggesting a potential upside of 232.64%. Pluri has a consensus target price of $12.00, suggesting a potential upside of 406.33%. Given Pluri's higher possible upside, analysts clearly believe Pluri is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Coya Therapeutics beats Pluri on 8 of the 15 factors compared between the two stocks.

How does Pluri compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Pluri (NASDAQ:PLUR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Pluri has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	5.03	-$344.51M	N/A	N/A
Pluri	$1.34M	19.08	-$22.58M	-$4.53	N/A

Pluri has a net margin of -2,162.08% compared to ALT5 Sigma's net margin of -2,483.94%. Pluri's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Pluri	-2,162.08%	N/A	-106.59%

ALT5 Sigma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Pluri has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

In the previous week, Pluri had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Pluri and 0 mentions for ALT5 Sigma. Pluri's average media sentiment score of 0.00 beat ALT5 Sigma's score of -0.47 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Pluri	Neutral

Pluri has a consensus target price of $12.00, suggesting a potential upside of 406.33%. Given Pluri's stronger consensus rating and higher probable upside, analysts plainly believe Pluri is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 25.9% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Pluri beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

How does Pluri compare to Aadi Bioscience?

Pluri (NASDAQ:PLUR) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Pluri has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	19.08	-$22.58M	-$4.53	N/A
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A

Pluri currently has a consensus price target of $12.00, indicating a potential upside of 406.33%. Given Pluri's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pluri is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

16.6% of Pluri shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aadi Bioscience has a net margin of -246.06% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Pluri has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

In the previous week, Pluri had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Pluri and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.35 beat Pluri's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pluri beats Aadi Bioscience on 9 of the 16 factors compared between the two stocks.

How does Pluri compare to enGene?

Pluri (NASDAQ:PLUR) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

enGene has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
enGene	N/A	-55.83%	-45.74%

In the previous week, enGene had 3 more articles in the media than Pluri. MarketBeat recorded 5 mentions for enGene and 2 mentions for Pluri. Pluri's average media sentiment score of 0.00 beat enGene's score of -0.13 indicating that Pluri is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Pluri has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	19.08	-$22.58M	-$4.53	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

Pluri has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, enGene has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

16.6% of Pluri shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pluri currently has a consensus target price of $12.00, indicating a potential upside of 406.33%. enGene has a consensus target price of $12.68, indicating a potential upside of 673.28%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

enGene beats Pluri on 8 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.62M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.52	18.74	21.22	25.66
Price / Sales	19.08	323.98	562.28	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-1.98	7.09	10.31	7.14
Net Income	-$22.58M	$24.45M	$3.57B	$335.98M
7 Day Performance	-5.95%	6.38%	6.43%	4.15%
1 Month Performance	-29.86%	2.43%	3.57%	2.54%
1 Year Performance	-48.03%	62.98%	34.07%	35.06%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	2.1227 of 5 stars	$2.37 flat	$12.00 +406.3%	-48.0%	$25.62M	$1.34M	N/A	150	Gap Up
NRXP NRx Pharmaceuticals	3.0212 of 5 stars	$2.98 -1.7%	$38.25 +1,184.9%	+22.9%	$108.15M	$1.23M	N/A	2
COYA Coya Therapeutics	2.2397 of 5 stars	$4.59 +0.3%	$16.00 +249.0%	-18.5%	$107.92M	$7.95M	N/A	6
AIFC ALT5 Sigma	0.1845 of 5 stars	$0.83 -2.4%	N/A	-90.0%	$105.68M	$24.84M	N/A	170	Gap Down
AADI Aadi Bioscience	N/A	$4.25 -9.6%	N/A	+155.1%	$104.96M	$25.07M	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors

PLUR vs. NRXP, COYA, AIFC, AADI, and ENGN

How does Pluri compare to NRx Pharmaceuticals?

Summary

How does Pluri compare to Coya Therapeutics?

Summary

How does Pluri compare to ALT5 Sigma?

Summary

How does Pluri compare to Aadi Bioscience?

Summary

How does Pluri compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pluri (PLUR) Competitors

PLUR vs. NRXP, COYA, AIFC, AADI, and ENGN

How does Pluri compare to NRx Pharmaceuticals?

Do institutionals and insiders hold more shares of NRXP or PLUR?

Which has more risk and volatility, NRXP or PLUR?

Is NRXP or PLUR more profitable?

Which has higher valuation and earnings, NRXP or PLUR?

Do analysts prefer NRXP or PLUR?

Does the media refer more to NRXP or PLUR?

Summary

How does Pluri compare to Coya Therapeutics?

Is COYA or PLUR more profitable?

Do institutionals & insiders hold more shares of COYA or PLUR?

Which has more volatility and risk, COYA or PLUR?

Which has stronger earnings & valuation, COYA or PLUR?

Does the media refer more to COYA or PLUR?

Do analysts prefer COYA or PLUR?

Summary

How does Pluri compare to ALT5 Sigma?

Which has higher valuation and earnings, AIFC or PLUR?

Is AIFC or PLUR more profitable?

Which has more volatility and risk, AIFC or PLUR?

Does the media prefer AIFC or PLUR?

Do analysts rate AIFC or PLUR?

Do insiders & institutionals believe in AIFC or PLUR?

Summary

How does Pluri compare to Aadi Bioscience?

Which has better valuation & earnings, PLUR or AADI?

Do analysts rate PLUR or AADI?

Do institutionals and insiders believe in PLUR or AADI?

Is PLUR or AADI more profitable?

Which has more risk & volatility, PLUR or AADI?

Does the media refer more to PLUR or AADI?

Summary

How does Pluri compare to enGene?

Is PLUR or ENGN more profitable?

Does the media prefer PLUR or ENGN?

Which has preferable valuation & earnings, PLUR or ENGN?

Which has more volatility and risk, PLUR or ENGN?

Do institutionals & insiders have more ownership in PLUR or ENGN?

Do analysts prefer PLUR or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools